Disease, Hodgkin

9 registered clinical trials studyying Disease, Hodgkin.

Status	Trial	Sponsor	Phase
Completed	A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Followin NCT01100502	Seagen Inc.	Phase 3
Completed	A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma NCT01060904	Seagen Inc.	Phase 1
Completed	Cardiac Safety Study of Brentuximab Vedotin (SGN-35) NCT01026233	Seagen Inc.	Phase 1
Completed	Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) NCT01026415	Seagen Inc.	Phase 1
Completed	A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study NCT00947856	Seagen Inc.	Phase 2
Completed	A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma NCT00848926	Seagen Inc.	Phase 2
Terminated	A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignan NCT00649584	Seagen Inc.	Phase 1
Completed	Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies NCT00430846	Seagen Inc.	Phase 1
No Longer Available	A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 o NCT01196208	Seagen Inc.	—